The European Journal of Public Health Advance Access originally published online on October 26, 2006
The European Journal of Public Health 2007 17(3):263-271; doi:10.1093/eurpub/ckl233
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Infectious and allergic diseases, cancer, and diabetes |
Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France
F. Sahajian1, P. Vanhems1, F. Bailly2, J. Fabry1, C. Trepo2, M. Sepetjan and Members of ADHEC1,*
1 Programme ADHEC, Laboratoire d'Épidémiologie et de Santé Publique Université de Lyon
2 Pôle de référence Hépatites C, Service d'hépato-gastroentérologie Hôtel-Dieu, Lyon, France
* Association for the Study of Hepatitis C Screening
Correspondence: Dr Frédéric Sahajian, ADHEC, Laboratoire d'Epidémiologie et de Santé Publique, Faculté de Médecine, Domaine Rockefeller, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France, tel: +33 04 78 77 75 33, fax: +33 04 78 77 75 71, e-mail: sahajian{at}rockefeller.univ-lyon1.fr
Received September 22, 2005 , accepted August 18, 2006
Background: A screening campaign for hepatitis C virus (HCV) infection was carried out in eight health centres of Lyon from June 2003 until March 2004. The population targeted for screening was underprivileged individuals without any social insurance, protected by Couverture Mutuelle Universelle or Aide Médicale Etat (AME), to estimate the prevalence of anti-HCV antibodies in this population and to identify associated risk factors. Methods: After training in HCV infection and screening, 43 general practitioners participated in the campaign. Information about patient socio-demographics and risk factors was collected prior to proposing screening serology. Blood samples were often taken in health centres. Follow-up of positive cases was organised via the Reference Centre of HCV Infection in Lyon with possible specialised consultations in health centres. Results: The average age of the 988 individuals in the campaign was 37 years; 51% were women; 54% had a foreign nationality; 21% lived in sheltered accommodation; 19% were lodged in third-party accommodation; 9% were homeless; and 57% possessed less than 
562 (Revenu Minimum d'Insertion level). Screening was not proposed to nine patients because of medico-psychological problems. The acceptance rate for screening was 98.8% (967/979), and testing was carried out on 97.6% of these subjects (944/967). The prevalence of anti-HCV antibodies in the sample was 4.7% (44/944) (95% CI = 3.4–6.2). Nearly 80% of positive cases were unknown prior to the campaign. Multivariate logistic regression modelling identified lifetime injection drug use [odds ratios (OR) = 15.99; P < 0.0001], lifetime medical care in a foreign country (OR = 4.46; P = 0.001), and wearing tattoos (OR = 2.75; P = 0.048) as significant risk factors for carrying anti-HCV antibodies. Characteristics independently associated with HCV seropositivity were age between 40 and 49 years, AME benefits, and no social insurance. Conclusion: Wide acceptance of screening, high prevalence of anti-HCV antibodies (much higher than in the French population in general), a high proportion of positive cases unknown beforehand, and satisfactory follow-up of seropositive patients are all factors which support the need for a screening campaign targeting HCV infection in underprivileged persons living in France.
Keywords: hepatitis C, screening, underprivileged population